All In Biotech

Drug Trial Radar · NCT03564691

Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab for Participants With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Oct 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

470

Actual

Start

Jul 11, 2018

Primary completion

Sep 26, 2025

Study completion Sep 26, 2025

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jun 21, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study consists of several parts: dose escalation, dose expansion, dose expansion in Chinese participants residing in China, and coformulation. Dose escalation is to evaluate the safety, tolerability, and preliminary efficacy of MK-4830 monotherapy administration (Arms A and B) and in combination with pembrolizumab (Arm C). Dose expansion is to evaluate the objective response rate (ORR) of MK-4830 in combination with pembrolizumab (Arms A-F); evaluate the safety and tolerability of MK-4830 administered in combination with pembrolizumab, carboplatin, and pemetrexed (Arm G) and of MK-4830 administered in combination with pembrolizumab and lenvatinib (Arm H); evaluate the safety, tolerability and ORR of MK-4830 in combination with pembrolizumab plus chemotherapy (Arms I-L); and evaluate the safety and tolerability of MK-4830 in combination with pembrolizumab in Chinese participants from China (Arm M). The coformulation part (Arm N) evaluates the safety and tolerability of MK-4830A (coformulation of MK-4830 800 mg + pembrolizumab 200 mg). There is no formal hypothesis testing in this study.

Conditions

  • Neoplasms

Interventions

  • MK-4830Drug

    MK-4830 will be administered intravenously (IV) Q3W. In Part C, MK-4830 will be administered after completion of pembrolizumab infusion. Dose escalation will proceed based on emerging safety and tolerability data of MK-4830 as monotherapy (Part A and B) and as combination therapy with pembrolizumab (Part C). For each dose level, an assessment will be made of the safety and tolerability data in order to define the next dose level to be tested.

  • PembrolizumabDrug

    Pembrolizumab will be administered at 200 mg IV Q3W.

  • CarboplatinDrug

    Carboplatin will be administered IV Q3W.

  • PemetrexedDrug

    Pemetrexed will be administered IV Q3W.

  • LenvatinibDrug

    Lenvatinib will be administered orally once daily.

  • PaclitaxelDrug

    Paclitaxel will be administered IV QW on Days 1, 8, and 15 of each 21-day cycle until disease progression or prohibitive toxicity (Arm J) and on Days 1, 8, and 15 Q4W until disease progression or prohibitive toxicity (Arm K).

  • CisplatinDrug

    Cisplatin will be administered IV Q3W.

  • MK-4830ABiological

    MK-4830A, a coformulation of MK-4830 800 mg + pembrolizumab 200 mg, will be administered IV Q3W.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-Limiting Toxicities (DLTs)Time frame: Cycle 1 (Up to 21 days)
  2. Number of Participants Who Experienced an Adverse Event (AE)Time frame: Up to approximately 27 months
  3. Number of Participants Who Discontinued Study Treatment Due to an AETime frame: Up to approximately 24 months
  4. Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or Response Assessment in Neuro-Oncology (RANO) as Assessed by InvestigatorTime frame: Up to approximately 24 months
  5. ORR per Modified RECIST (mRECIST) 1.1 as Assessed by InvestigatorTime frame: Up to approximately 24 months

Locations

37 sites in 12 countries. Site status is shown where the registry gives one.

  • University of California at San Francisco ( Site 0004)

    San Francisco, California

  • Henry Ford Health System ( Site 0002)

    Detroit, Michigan

  • Washington University ( Site 0003)

    St Louis, Missouri

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0005)

    Hackensack, New Jersey

  • Laura and Isaac Perlmutter Cancer Center ( Site 0008)

    New York, New York

  • Ohio State University Arthur G James Cancer Hospital & Richard J Solove Research Institute ( Site 00

    Columbus, Ohio

  • South Texas Accelerated Research Therapeutics, LLC (START) ( Site 0001)

    San Antonio, Texas

  • Utah Cancer Specialists ( Site 0011)

    Salt Lake City, Utah

  • Seattle Cancer Care Alliance ( Site 0010)

    Seattle, Washington

  • Liverpool Hospital-Medical Oncology ( Site 0250)

    Liverpool, New South Wales, Australia

  • Princess Alexandra Hospital ( Site 0253)

    Brisbane, Queensland, Australia

  • Juravinski Cancer Centre ( Site 0034)

    Hamilton, Ontario, Canada

  • The Ottawa Hospital ( Site 0031)

    Ottawa, Ontario, Canada

  • Princess Margaret Cancer Centre ( Site 0033)

    Toronto, Ontario, Canada

  • The First Hospital of Jilin University ( Site 0803)

    Changchun, Jilin, China

  • Shanghai Chest Hospital-Oncology department ( Site 0801)

    Shanghai, Shanghai Municipality, China

  • West China Hospital of Sichuan University ( Site 0804)

    Chengdu, Sichuan, China

  • Hôpital Européen Georges Pompidou ( Site 2003)

    Paris, Île-de-France Region, France

  • Centre Oscar Lambret ( Site 2002)

    Lille, Nord, France

  • Centre Hospitalier Universitaire de Poitiers ( Site 2000)

    Poitiers, Vienne, France

  • Euromedica General Clinic of Thessaloniki-Oncology Unit ( Site 0112)

    Thessaloniki, Greece

  • European Interbalkan Medical Center ( Site 0111)

    Thessaloniki, Greece

  • University General Hospital of Heraklion ( Site 0110)

    Heraklion, Irakleio, Greece

  • Rambam Health Care Campus-Oncology Division ( Site 0042)

    Haifa, Israel

  • Rabin Medical Center ( Site 0043)

    Petah Tikva, Israel

  • Chaim Sheba Medical Center. ( Site 0044)

    Ramat Gan, Israel

  • Sourasky Medical Center ( Site 0041)

    Tel Aviv, Israel

  • Japanese Foundation for Cancer Research ( Site 0401)

    Tokyo, Japan

  • National Cancer Center Hospital East ( Site 0400)

    Kashiwa, Chiba, Japan

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (

    Warsaw, Masovian Voivodeship, Poland

  • Uniwersyteckie Centrum Kliniczne ( Site 0151)

    Gdansk, Pomeranian Voivodeship, Poland

  • Wits Clinical Research ( Site 0213)

    Johannesburg, Gauteng, South Africa

  • The Oncology Centre ( Site 0212)

    Durban, KwaZulu-Natal, South Africa

  • Cancercare Rondebosch Oncology ( Site 0210)

    Cape Town, Western Cape, South Africa

  • Severance Hospital Yonsei University Health System ( Site 0300)

    Seoul, South Korea

  • Centro Integral Oncologico Clara Campal START Madrid ( Site 0102)

    Madrid, Spain

  • Instituto Catalan de Oncologia ICO - Hospital Duran i Reynals ( Site 0101)

    L'Hospitalet de Llobregat, Barcelona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.